KPKyla N. Price

Kyla N. Price

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kyla N. Price has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • National Institutes of Health Dermatology Funding Trends: 2020–2024

    by Aditya Joshi, Lauren Gawey, Morgan Harrison, Kyla N. Price, Raveena Ghanshani, David J. Griego, Jennifer L. Hsiao, Vivian Y. Shi


  • Open Access

    Academic dermatology chair and chief characteristics

    by Alyssa M. Thompson, Swetha Atluri, Danielle Yee, Kyla N. Price, Jennifer L. Hsiao, Vivian Y. Shi


  • Topography of lesion progression in hidradenitis suppurativa

    by Jennifer M. Fernandez, Omar H. Rizvi, Kendra D. Marr, Aleksi J. Hendricks, Melody Maarouf, Kyla N. Price, Catherine M. Ludwig, Jennifer L. Hsiao, Vivian Y. Shi


  • Open Access

    Provider perspectives on the management of hidradenitis suppurativa in pregnancy – A survey study

    by Erin K. Collier, Kyla N. Price, Tristan Grogan, Jennifer M. Fernandez, Justine R. Seivright, Raed Alhusayen, Afsaneh Alavi, Iltefat H. Hamzavi, Michelle A. Lowes, Martina J. Porter, et al.


  • Open Access

    Art of prevention: Practical tips for improving adherence to treatments for older patients in dermatology

    by Kyla N. Price, Madison Grinnell, Daniel Butler, Amit Shah

    Given demographic changes and increases in longevity, physicians will see increasing numbers of patients over the age of 65 years. As the population ages, adapting and optimizing patient care to better serve the needs of older patients should be a priority. The goal of this review is to shed light on potential barriers affecting treatment adherence and to improve clinical care for older adults with dermatologic conditions. We provide practical strategies to help overcome these barriers and provide suggestions to address the impact of functional limitations on topical medication adherence. Some less apparent risks of treatment, such as fall risks with topical treatments, are also discussed, along with issues such as cost of treatments and prescribing considerations for patients who reside in facilities.


  • Physician perspectives on complementary and alternative medicine in hidradenitis suppurativa

    by Kyla N. Price, Erin K. Collier, Tristan Grogan, Jennifer M. Fernandez, Raed Alhusayen, Afsaneh Alavi, Iltefat H. Hamzavi, Michelle A. Lowes, Martina J. Porter, Jennifer L. Hsiao, et al.

    Hidradenitis suppurativa (HS) is a chronic and often debilitating inflammatory condition characterized by frequent nodules, abscesses, sinus tracts, and scars impacting the intertriginous areas. Many patients with HS often report limited treatment success and symptom coverage with conventional therapies. Recent studies have reported the widespread use of complementary and alternative medicine (CAM) among patients with HS. In this study, our aim was to examine current physician practice patterns, opinions, and comfort with recommending CAM. Our results indicate that provider comfort and opinions on CAM varied based on the provider's experiences, demographics, and the CAM modality itself. Overall, nearly two‐thirds (n = 30, 61.2%) of respondents agreed that CAM and conventional medicine were more effective together than either alone. Meanwhile, 44.9% (n = 22) of respondents routinely recommend CAM while 64.6% (n = 31) of respondents reported that they are routinely asked about CAM. The majority (n = 41, 83.7%) of respondents indicated a lack of scientific evidence in the medical literature as a barrier to recommending CAM along with efficacy concerns (n = 34, 69.4%) and ability to recommend reputable CAM products (n = 32, 65.3%) and practitioners (n = 32, 65.3%). Future investigations are warranted to establish a better understanding of the efficacy and benefit of CAM methods in conjunction with conventional methods.


  • Open Access

    Gender gaps in National Institutes of Health dermatology grant recipients

    by Alyssa M. Thompson, Kyla N. Price, Swetha Atluri, Danielle Yee, Jennifer L. Hsiao, Vivian Y. Shi

    Understanding the demographics and scholarly merit among National Institutes of Health (NIH) award recipients can help guide future applicants in the field of dermatology. Herein, we aimed to explore gender gaps in NIH award recipient demographics and scholarly merits for dermatology-related projects. Projects funded by the National Institutes of Arthritis and Musculoskeletal and Skin Diseases between 2015 and 2019 related to dermatology were extracted using the NIH Research Portfolio Online Reporting Tools database. The number of publications and h-index of each award recipient were collected using the Scopus database. The 2019 Blue Ridge Institute for Medical Research report was used to determine the top 20 NIH-funded dermatology departments/divisions. Between 2015 and 2019, there were 35.1% more unique male than unique female recipients. Award recipients had an average of 116.7 total publications and an average h-index of 37.1. However, men also had more than half as many publications and a >37% higher average h-index. Gender gaps in research merit, as well as number and type of awards, are reduced among recipients affiliated with a top 20 NIH-funded institution. A higher number of awards were granted to male recipients. Men had a higher mean publication number and h-index compared with their female counterparts. Increased support, resources, and mentorship opportunities to women in research may help mitigate these gaps.


  • National Institutes of Health Dermatology Funding Trends 2015–2019

    by Kyla N. Price, Erin K. Collier, Swetha Atluri, Jennifer L. Hsiao, Vivian Y. Shi


  • Facilitating Clinical Trials Participation of Low Socioeconomic Status Patients

    by Kyla N. Price, Alexis B. Lyons, Iltefat H. Hamzavi, Jennifer L. Hsiao, Vivian Y. Shi

    Socioeconomic status represents social standing measured by the combination of education, income, and occupation [1]. Financial barriers and lack of education generate a number of obstacles to receiving adequate healthcare and treatment. A recent study exploring demographics of cancer clinical trial participants found that patients with an annual household income of less than USD 50,000 had 32% lower odds of trial participation than patients with above USD 50,000 [2]. There is limited data reporting low socioeconomic status (LSES) and participation in dermatology clinical trials; however, it is not unlikely that financial barriers result in similar disparities. These findings support the need to represent and care for LSES groups in clinical trials.


  • Open Access

    Characterizing perimenstrual flares of hidradenitis suppurativa

    by Erin K. Collier, Kyla N. Price, Tristan R. Grogan, Haley B. Naik, Vivian Y. Shi, Jennifer L. Hsiao

    Hidradenitis suppurativa (HS) predominantly affects women of childbearing age, and sex hormones are thought to play a role in HS pathogenesis. However, there is a paucity of data regarding the pattern of HS perimenstrual flares, as well as patient responses to hormone-based therapies. We aimed to characterize the temporal pattern of perimenstrual flares, as well as factors associated with perimenstrual flares. We also sought to investigate responses to hormonal therapies in women with HS. An anonymous web-based questionnaire was distributed to various online HS support groups in May 2020. A total of 283 participants met the inclusion criteria as adult women who self-reported having HS and menstrual cycles. The majority (176 of 282 women; 62.4%) reported HS worsening with menses, and 86.9% (153 of 176 women) noted that perimenstrual HS flares occurred always or often. Most women (138 of 175 women; 78.9%) reported that their HS flared in the week preceding menses. Perimenstrual HS flares were more likely in women with a family history of HS compared with those without (49.6% vs. 28.2%; p = .019). More than a third of respondents who had been treated with spironolactone reported improvement of HS symptoms, but more than a quarter of participants who used medroxyprogesterone acetate or used a hormonal intrauterine device reported worsened HS symptoms. Female patients with HS have high rates of perimenstrual HS flares, specifically during the week preceding the onset of menses. Additional investigations on the role of sex hormones in HS pathogenesis and the efficacy of hormone-based therapies are warranted.